Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + epirubicin + cyclophosphamide + tecemotide
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of three chemotherapy drugs (docetaxel, epirubicin, and cyclophosphamide) plus tecemotide, an investigational therapeutic cancer vaccine. Docetaxel is a taxane that inhibits cell division by disrupting microtubule function. Epirubicin is an anthracycline that intercalates with DNA and inhibits topoisomerase II. Cyclophosphamide is an alkylating agent that cross-links DNA. Tecemotide is a synthetic lipopeptide vaccine designed to induce a cellular immune response against cancer cells expressing MUC1, a glycoprotein antigen overexpressed in various cancers including breast cancer.
02
Targets
DNAMUC1 (Mucin-1 Antigen)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on docetaxel + epirubicin + cyclophosphamide + tecemotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + epirubicin + cyclophosphamide + tecemotide.